BioAgilytix

With free payload circulating at pg/mL concentrations against an ADC dosed in the µg/mL range, even minimal linker cleavage can impact PK results. Learn how LC-MS supports free payload analysis through assay design, linker stability controls, and light-sensitivity testing.

LBA has been the gold standard for biologics PK for decades, but it measures one analyte at a time. Learn how hybrid LBA-LC-MS enables multiplex analysis for multidomain therapeutics, providing multiple readouts from a single sample.

One global standard, wherever your program runs. Lynn Kamen, PhD and Dave Beyerlein explain how harmonized LC/MS methods enable seamless assay transfer and regulatory alignment across regions.

Complex therapeutic modalities challenge traditional bioanalytical approaches. For ADCs, AOCs, multidomain proteins, and RNA therapeutics, LC-MS enables measurement of the components that drive pharmacological activity. Access the full webinar to learn more.

Why choose LC/MS to analyze the PK of large molecules? Lynn Kamen, PhD and Dave Beyerlein cover the regulatory considerations and where LC/MS delivers the most value.

Selecting the optimal platform for RNA bioanalysis is essential in program development. Leverage BioAgilytix LC/MS, PCR & hELISA platforms to obtain the data you need to advance your RNA therapeutic.